India Globalization Capital Files Patent for Hyalolex Formulation

Prepares for Accelerated National Product Launch

BETHESDA, Md.–(BUSINESS WIRE)–#Alzheimers–India Globalization Capital, Inc. (NYSE Amex:IGC) today announced that
it has filed a method and composition patent with the U.S.P.T.O. for the
formulation of Hyalolex (IGC-507), which helps address some symptoms of
Alzheimer’s disease including the buildup of plaques and tangles,
anxiety, aggression and sleep disorders among others.

This patent filing enables IGC to pursue the commercialization of this
formulation in U.S. states where medical cannabis is legal, as well as
in selected European countries. As previously announced, IGC will start
its marketing activities in Puerto Rico with subsequent initiatives in
ten key markets in the U.S.

In addition, the new patent filing allows the Company to disclose its
specific method of manufacturing Hyalolex and specific active
ingredients to appropriate health departments, processors, growers,
doctors, caregivers, patients and dispensaries, which will be integral
to the acceleration of IGC’s marketing efforts. According to CEO Ram
Mukunda, the Company will also incorporate the formulation and active
ingredients in its website and through its presentations. “As this
evolves our Company will evidence its goal of becoming a market leader
in specific areas where we will have a head-start, such as Alzheimer’s,”
he said.

The Company is launching Hyalolex in Puerto Rico, as previously
reported, in part because the Latino population is especially
susceptible to Alzheimer’s disease with a much higher likelihood of
contracting the disease. In total, there are over 5.5 million adults
with Alzheimer’s in the U.S. and over 44 million worldwide. After
launching marketing initiatives for Hyalolex in Puerto Rico, IGC will
commence marketing and licensing arrangements in states including
Maryland, Washington, D.C. and California.

By the end of the year, Mukunda says he expects IGC to have its
Alzheimer’s product in 10 U.S. states. “In the process, we will build a
distribution and brand presence that we can leverage for our other
products and bring relief to those afflicted with this difficult
diagnosis,” he said.

About IGC

IGC has two lines of business, (i) a legacy commodity trading, and
infrastructure business, and (ii) a cannabis based complimentary
medicines business that has developed a lead product for treating
Alzheimer’s patients. IGC recently announced that it is working on using
blockchain to address issues specific to the cannabis industry including
transactional difficulties, product labeling, product identification
assurance (PIA), and product origin assurance (POA). IGC is based in
Maryland, USA.
For more information please visit www.igcinc.us
Follow
us on Twitter @IGCIR and Facebook.com/IGCIR/

Forward-looking Statements

Please see forward looking statements as discussed in detail in IGC’s
Form 10K for fiscal year ended March 31, 2017, and in other reports
filed with the U.S. Securities and Exchange Commission.

Contacts

For IGC:
Claudia Grimaldi, 301-983-0998